Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of glucose for cellular metabolism, primarily via glycolysis and the Krebs cycle, to produce ATP. Sodium chloride maintains fluid and electrolyte balance, acting as a source of sodium and chloride ions essential for osmotic pressure and acid-base homeostasis.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Fluid and electrolyte replacement in patients with hypotonic dehydration,Maintenance of hydration and electrolyte balance,Provision of calories in patients requiring parenteral nutrition
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion: 100-200 m L/hour per 70 kg adult; rate adjusted based on fluid and electrolyte needs, typically 0.5-4 m L/kg/hour.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Not applicable; dextrose and electrolytes are endogenous substances, not subject to classic elimination half-life. Plasma glucose half-life is ~15-20 minutes in euglycemic conditions due to rapid cellular uptake.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose undergoes cellular metabolism via glycolysis and the Krebs cycle; sodium and chloride are renally excreted and regulated by the kidneys.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Dextrose: primarily metabolized to CO2 and water; <1% excreted unchanged renally. Sodium chloride: electrolytes are reabsorbed or excreted renally; no specific elimination pathway.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
None (0%): dextrose and sodium chloride are not bound to plasma proteins.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Dextrose: Vd ~0.2 L/kg (limited to extracellular fluid); sodium distributes primarily in extracellular fluid (Vd ~0.15-0.3 L/kg).
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100% (complete bioavailability). Not applicable for other routes.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
GFR <30 m L/min: Reduce infusion rate by 50-75% and monitor serum sodium; avoid in anuria.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
Child-Pugh Class B or C: No specific dose adjustment required; monitor for fluid overload and hyponatremia.
No dosage adjustment required for hepatic impairment.
Intravenous infusion: 0.5-4 m L/kg/hour, adjusted based on maintenance fluid requirements (e.g., 4-2-1 rule) and clinical status.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Start at lower end of infusion rate (e.g., 0.5-1 m L/kg/hour) due to decreased renal function and higher risk of fluid overload; monitor serum sodium and volume status.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Monitor serum glucose, electrolytes, and fluid balance regularly,Risk of hyperglycemia in diabetic patients,Volume overload in patients with heart failure or renal impairment,Extravasation risk during IV administration,May cause electrolyte imbalances with prolonged use
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperglycemia or glucose intolerance,Hypernatremia or hyperchloremia,Severe renal impairment with oliguria,Severe dehydration (avoid hypotonic solutions in shock),Known allergy to any component
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No direct food interactions with this IV solution. However, oral intake may affect electrolyte balance; patients on sodium restriction should avoid high-sodium foods.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Dextrose and sodium chloride at these concentrations are generally not teratogenic. Glucose is a physiologic nutrient and sodium chloride is an electrolyte; no fetal risks are reported when used appropriately. Trimester risk: Category C (not shown to be harmful, but no controlled studies).
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Compatible with breastfeeding. Dextrose and sodium chloride are normal blood constituents. M/P ratio not applicable; both compounds transfer into breast milk in negligible amounts without adverse effects.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy increases plasma volume, possibly requiring higher volumes of IV fluids. Pharmacokinetic changes: increased GFR may affect electrolyte excretion; dose adjustments are not typically needed but individualize based on maternal hydration status and serum glucose/electrolytes.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This solution provides 85 m Eq/L sodium and 77 m Eq/L chloride. Use with caution in patients with heart failure, renal impairment, or hypertension due to sodium load. Monitor serum electrolytes and fluid balance. Not for peripheral administration if osmolarity >900 m Osm/L (this solution is isotonic). Assess injection site for phlebitis or extravasation.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This intravenous solution provides fluids and electrolytes, not food calories.,Report any signs of fluid overload: swelling, shortness of breath, or rapid weight gain.,Inform your healthcare provider if you have high blood pressure, heart problems, or kidney issues.,Tell your nurse immediately if you experience pain, redness, or swelling at the IV site.,This solution contains sodium; follow any dietary sodium restrictions as advised by your doctor.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides a source of glucose for cellular metabolism, primarily via glycolysis and the Krebs cycle, to produce ATP. Sodium chloride maintains fluid and electrolyte balance, acting as a source of sodium and chloride ions essential for osmotic pressure and acid-base homeostasis.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is: Intravenous infusion: 100-200 m L/hour per 70 kg adult; rate adjusted based on fluid and electrolyte needs, typically 0.5-4 m L/kg/hour.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride at these concentrations are generally not teratogenic. Glucose is a physiologic nutrient and sodium chloride is an electrolyte; no fetal risks are repo. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.